Crossmark

Budget impact analysis of neoadjuvant nivolumab for non-small cell lung cancer in the Chilean public healthcare system: An exploratory economic assessment

Crossref DOI link: https://doi.org/10.1007/s12094-025-03872-7

Published Online: 2025-03-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Paredes-Fernández, Daniela

Lenz-Alcayaga, Rony https://orcid.org/0000-0002-6417-3029
Orlandi-Jorquera, Francisco
Funding

Funding for this research was provided by:

Bristol Myers Squibb Chile (CW39161)
License Information

Text and Data Mining valid from 2025-03-02

Version of Record valid from 2025-03-02
More Information

Article History

Received: 4 November 2024

Accepted: 8 February 2025

First Online: 2 March 2025

Declarations

:

: Bristol Myers Squibb Chile supported the research leading to these results. The investigators maintained complete independence throughout all study phases, from design to the interpretation of the results. Bristol Myers Squibb Chile was not involved in data collection, analysis, or manuscript preparation.

Document is current

Any future updates will be listed below